Digestives & Intestinal Remedies - Israel

In Israel, the revenue generated in the Digestives & Intestinal Remedies market market in 2024 is US$52.15m.
This market is projected to experience an annual growth rate of 2.45% from 2024 to 2029 (CAGR 2024-2029).
When compared globally, China generates the highest revenue in this market, amounting to US$4.41bn in 2024.
In terms of per person revenues, in Israel generates US$5.60 in 2024.
Israel's Digestives & Intestinal Remedies market is witnessing a surge in demand for natural and herbal remedies.

Definition:
The Digestives and Intestinal Remedies market comprises over-the-counter natural and synthetic digestive agents and remedies against gastrointestinal complaints. Digestives include preparations in the form of pills, powder, capsules, liquids, solutions, suspensions, drops and suppositories. Not included are prescription medicines, preparations that are against the state law or are not explicit digestive drugs (e.g. painkillers). Among the top-selling digestives are Perenterol, Iberogast, Dulcolax and Buscopan Plus. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Additional information:
The Digestives and Intestinal Remedies market comprises revenues, average revenue per capita. Sales channels show online and offline revenue. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included.
For more information on the data displayed, use the info button next to the boxes.

Natural and synthetic agents
Digestive medicines
Remedies against gastrointestinal complaints

Prescription medicines
Homeopathic remedies
Tea

The Digestives & Intestinal Remedies market in Israel has been experiencing steady growth in recent years. Customer preferences in the market have shifted towards natural and organic products, as consumers become more health-conscious and seek alternatives to traditional medicines. There is a growing demand for digestive remedies that are made from natural ingredients and are free from artificial additives. This trend is in line with the global movement towards healthier and more sustainable lifestyles.Another trend in the market is the increasing popularity of probiotics. Probiotics are live bacteria and yeasts that are beneficial for digestive health. They are commonly found in yogurt and other fermented foods, but are also available in supplement form. Probiotics have gained popularity in Israel as consumers recognize the importance of maintaining a healthy gut microbiome. This trend is driven by the growing body of scientific research that supports the use of probiotics for digestive health.Local special circumstances in Israel have also contributed to the development of the Digestives & Intestinal Remedies market. The country has a high prevalence of digestive disorders, such as irritable bowel syndrome and gastroesophageal reflux disease. This has created a large customer base for digestive remedies, driving the demand for products in the market.Furthermore, Israel has a strong healthcare system and a high level of healthcare expenditure per capita. This has enabled consumers to have easy access to a wide range of digestive remedies and has supported the growth of the market.Underlying macroeconomic factors have also played a role in the development of the Digestives & Intestinal Remedies market in Israel. The country has a stable economy and a high standard of living, which has led to increased disposable income among consumers. This has allowed them to spend more on healthcare products, including digestive remedies.In conclusion, the Digestives & Intestinal Remedies market in Israel is developing due to customer preferences for natural and organic products, the increasing popularity of probiotics, local special circumstances such as a high prevalence of digestive disorders, and underlying macroeconomic factors such as a stable economy and high disposable income. The market is expected to continue growing in the coming years as consumers prioritize their digestive health and seek effective remedies for digestive disorders.

Data coverage:

Data encompasses B2C spend. Figures are based on the OTC Pharmaceuticals market values, representing revenues generated by both product sales which take place exclusively in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use data from national statistical offices, international institutions, trade associations, and self-medication associations. Next, we use relevant key market indicators and data from country-specific associations, such as consumer healthcare spending, out-of-pocket healthcare expenditure, health system accessibilities, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. Whereas this market covers only OTC drugs, the Statista Pharmaceuticals market covers both OTC and prescription drugs.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.